Post-Reperfusion Myocardial Infarction
Long-Term Survival Improvement Using Adenosine Regulation With Acadesine
Dennis T. Mangano, PhD, MD*,
Yinghui Miao, MD, MS,
Iulia C. Tudor, PhD,
Cynthia Dietzel, MDfor the for the Investigators of the Multicenter Study of Perioperative Ischemia (McSPI) Research Group the Ischemia Research and Education Foundation (IREF)
Ischemia Research and Education Foundation (IREF), San Bruno, California

View larger version (15K):
[in a new window]
|
Figure 2 Kaplan-Meier analysis of 2-year survival according to with or without postoperative myocardial infarction (MI) among the 2,698 study patients.
|
|

View larger version (35K):
[in a new window]
|
Figure 3 (A) Kaplan-Meier analysis of 2-year survival according to the use or non-use of acadesine among the 100 study patients who sustained post-reperfusion myocardial infarction (MI). (B) Two-year mortality by-MI and by-treatment.
|
|

View larger version (23K):
[in a new window]
|
Figure 4 Two-year mortality: acadesine versus placebo by patient characteristic. ASA = acetylsalicylic acid; BB = beta-blocker; CABG = coronary artery bypass graft; CCB = calcium channel blocker; CHF = congestive heart failure; DYS = dysrhythmia; HX = history of; LLA = lipid-lowering agents; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty; UA = unstable angina.
|
|
|